About Midatech Ltd/
the Midatech Group

Midatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self assembling biocompatible nanoparticle technology.

The company has successfully employed its nanotechnology platform and know-how to transition discovery and engineering sciences to practical nanomedicine applications through in-house and partnered drug development programs. Midatech’s unique nanoparticles allow rapid targeting of drugs or drug combinations to specific tissues or cells as well as potentially enabling transport across the blood brain barrier.

Midatech’s mission is to become the global leader and centre of competence in the nanomedicine arena.

Midatech is a privately-owned Group of Companies with a strong patent estate.

Product Pipeline

Midatech’s nanomedicine development programs focus on:

  • metabolic disorders, including diabetes
  • oncology, including traditional onco-drugs and si/shRNA drugs

Midatech’s advanced development plans focus on:

  • vaccines, including prophylactic vaccines and immunotherapy for cancer and chronic viral disorders

In-house and collaborative projects are at various stages of development. Our most advanced product is poised to undergo Phase I/II clinical trials with a projected completion during Q2 2011.

Partnering

In addition to specific pipeline partnerships, Midatech is working with partners on developing the unique properties of drug-nanoparticle combinations to provide a drug delivery platform that will:

  • offer a second patent life for approved or generic drugs
  • increase drug efficacy by overcoming toxicity or solubility problems that are encountered during drug development
  • enhance uptake via novel delivery routes

News

17 Aug 2010 – Midatech and Monosol Rx Announce Filing of Joint Patent Application for Nanoparticle Film Delivery Systems. (PDF, 159 kB)

12 Jul 2010 – Midatech and Immunotope Form Joint Venture, Syntara LLC, for the Development of Immune Therapies. (PDF, 184 kB)

24 Jun 2010 – Midatech Expands Collaboration with Monosol Rx to Deliver Peptides Utilizing Nanotechnology and PharmFilm® Drug Delivery Technology. (PDF, 158 kB)

Company/Contact Details

Midatech Ltd

Professor Thomas Rademacher
Chairman and Chief Executive Officer

Storme Moore-Thornicroft
Vice President, Corporate Management
T: +44 1235 528 022

The company’s corporate capabilities are further supported by the following wholly owned subsidiaries: Midatech US, Pharmida AG and Midatech Biogune S.L.

Business Development, Partnering and Licensing

Europe

Peter Sorg
T: + 41 797 079 464

USA
Midatech US

Sterling Johnson
President
T: +1 760 936 1024

Drug Development

Pharmida AG

Jan Mous
Chief Executive Officer
T: + 41 793 522 314

cGMP Manufacturing and Research

Midatech Biogune S.L.

Justin Barry
Chief Executive Officer
T: + 34 944 034 020

Events

NanoBio Zurich – 3rd International NanoBio Conference

24-27 August, ETH, Zurich, Switzerland

BioPharm America 2010

15-17 September, Boston, USA